Completed PHASE2 INTERVENTIONAL 3-arm NCT00730288

Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects

Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Previously Immunised With an Investigational Dengue or Yellow Fever Vaccine

Sponsor: Sanofi

Conditions Dengue Dengue Fever Dengue Hemorrhagic Fever Dengue Virus

Interventions Chimeric dengue serotype (1, 2, 3, 4)

Updated 5 times since 2017 Last updated: Feb 23, 2018 Started: Aug 31, 2006 Primary completion: Aug 31, 2007 Completion: Jan 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Dengue and Dengue Fever, this trial is completed. The trial is conducted by Sanofi and has accumulated 5 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Study Description(click to expand)

This study will evaluate a dengue tetravalent vaccine formulation in subjects aged 18 to 40 years and previously immunised with a dengue or YF vaccine.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Adelaide, Australia